Basf Aktiengesellschaft

Abbott Gmbh & Co Kg

Abbvie Biotechnology Ltd

Warner-lambert Company

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Subhashis Banerjee

Daniel Edward Tracey

Jochen G Salfeld

Michael Paskind

Geertruida Machteld Veldman

Boris Labkovsky

Zehra Kaymakcalan

Michael White

Michael Roguska

Paul Sakorafas

Nicholas W Warne

Thor Las Holtet

Angela Widom

Elaine Joy Derbyshire

John Gawain Elvin

Sara Carmen

Alexander Robert Duncan

Stuart Friedrich

Sarah Leila Du Fou

Stephen Smith

Amy Venturini

Angela Myles

Mark Weinberg

Rebecca S Hoffman

Elliot Keith Chartash

Steven Alan Fischkoff

George Richard Granneman

Lori K Taylor

Philip Yan

Anwar Murtaza

Hamish John Allen

William T Barchuk

Clive E Spiegler

Catherine R Kostlan

John C Hodges

Robert V Talanian

Kenneth Dale Brady

Angela Kantor

Andreas Haupt

Teresa Barlozzari

Tariq Ghayur

Ping Li

Tara Seshadri

Les Sekut

Adam Carter

Steven Fischkoff

Eliot Keith Chartash

The invention describes methods of treating erosive polyarthritis comprising administering a TNF&#x3b1; antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF&#x3b1; antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Use of TNF&#x3b1; inhibitor for treatment of psoriasis

Use of TNF&#x3b1; inhibitor for treatment of psoriatic arthritis

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Use of TNF-alpha inhibitor for treatment of psoriasis

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

Human antibodies that bind human IL-12

Human antibodies that bind human IL-12 and methods for producing

A transgenic mouse having somatic and germ cells in which at least one allele of an endogenous interleukin-1.beta. converting enzyme (ICE) gene is functionally disrupted is provided. The mouse may be heterozygous or, more preferably, homozygous for the ICE gene disruption. In homozygous mice, secretion of mature interleukin-1.beta. and interleukin-1.alpha. is substantially reduced relative to non-mutant mice. The mice of the invention can be used as positive controls to evaluate the efficacy of ICE inhibitors and to identify disease conditions that can be treated with ICE inhibitors. A transgenic mouse having functionally disrupted endogenous ICE genes but which has been reconstituted with a human ICE gene is also provided. This mouse can be used to identify agents that inhibit human ICE in vivo. Nucleic acid constructs for functionally disrupting an endogenous ICE gene in a host cell, recombinant vectors including the nucleic acid construct, and host cells into which the nucleic acid construct has been introduced are also encompassed by the invention.

Transgenic knockout mouse having functionally disrupted interleukin-1.beta.

Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-.gamma. in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-.gamma. inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-.gamma. in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

Methods and compositions for modulating responsiveness to corticosteroids

The present invention provides compositions and methods for the treatment of rheumatoid arthritis in a subject wherein one or more compounds of Formula I as defined herein alone or in combination with one or more other antiarthritic drugs provide suppression of rheumatoid arthritis.

Methods and compositions for treating rheumatoid arthritis

The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).

N-substituted glutamic acid derivatives with interleukin-1.beta.

N-substituted glutamic acid derivatives with interleukin-1 .beta.

Growing community of inventors

Hamden, CT, United States of America

Subhashis Banerjee